![The SWITCH1 trial: Proving that Lantus/Basaglar has a higher Hypocglycaemia rate than Tresiba | Diabettech - Diabetes and Technology The SWITCH1 trial: Proving that Lantus/Basaglar has a higher Hypocglycaemia rate than Tresiba | Diabettech - Diabetes and Technology](https://i0.wp.com/www.diabettech.com/wp-content/uploads/2016/09/Overall-Basal.jpg?resize=981%2C538)
The SWITCH1 trial: Proving that Lantus/Basaglar has a higher Hypocglycaemia rate than Tresiba | Diabettech - Diabetes and Technology
![Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial - The Lancet Diabetes Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial - The Lancet Diabetes](https://www.thelancet.com/cms/asset/a6f45dad-0f40-48ae-8f89-2971051b7477/gr1.jpg)
Switching to once-weekly insulin icodec versus once-daily insulin degludec in individuals with basal insulin-treated type 2 diabetes (ONWARDS 2): a phase 3a, randomised, open label, multicentre, treat-to-target trial - The Lancet Diabetes
![Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements - Scott M. Pearson, Jennifer M. Trujillo, 2018 Conversion from insulin glargine U-100 to insulin glargine U-300 or insulin degludec and the impact on dosage requirements - Scott M. Pearson, Jennifer M. Trujillo, 2018](https://journals.sagepub.com/cms/10.1177/2042018818760962/asset/images/large/10.1177_2042018818760962-fig1.jpeg)